Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Both Cohorts 1 and 2:
* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* HIV/HBV co-infected adult males and non-pregnant and non-lactating females
* No evidence of hepatocellular carcinoma (HCC) or clinical or imaging evidence of cirrhosis (ascites, variceal bleeding, encephalopathy).
\--- Subjects should have documentation of an abdominal ultrasound in the 12 months prior to screening, or an abdominal ultrasound at screening, demonstrating the absence of cirrhosis and HCC.
* Acute Hepatitis A virus (HAV) immunoglobulin M (IgM) negative
* Hepatitis C virus (HCV) Ab negative, or HCV Ab positive with negative HCV RNA
* Hepatitis D virus (HDV) Ab negative, or HDV Ab positive with negative HDV RNA
* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula
* CD4+ count of \> 200 cells/μL
* Chronic HBV infection as defined by
* HBsAg positive for ≥ 6 months Or
* HBsAg positive at screening and either hepatitis B e antigen (HBeAg) or HBV DNA positive ≥ 6 months Or
* At screening: positive total hepatitis B core antibody (HBcAb) and negative immunoglobulin M antibody to hepatitis B core antigen (HBcIgM) antibody, and
* HBsAg positive, or
* HBeAg positive, or
* HBV DNA positive
Cohort 1 (HIV and HBV treatment naive) only:
* No current or prior anti-HIV treatment, including antiretroviral medications received for prevention (PrEP), or post exposure prophylaxis (PEP)
* No current or prior anti-HBV treatment
* Plasma HIV-1 RNA level ≥ 500 copies/mL at screening
* Screening HBV DNA ≥ 3 log10 IU/mL and \< 9 log10 IU/mL
Cohort 2 (HIV suppressed) only:
* Receiving current antiretroviral regimen for at least 4 consecutive months
* No current or prior regimen containing 3 active anti-HBV agents (i.e. cannot be on tenofovir alafenamide (TDF)/emtricitabine (FTC)/Entecavir or TDF/lamivudine(3TC)/Entecavir)
* Maintained plasma HIV-1 RNA \< 50 copies/mL for 6 consecutive months prior to and at the time of the screening visit. Unconfirmed virologic evaluation of ≥ 50 copies/mL after previously reaching viral suppression (transient detectable viremia, or "blip") and prior to screening is acceptable
* Documented positive HIV antibody test
* Screening HBV DNA \< 9 log10 IU/mL
You may not be if
Females who are breastfeeding
Positive serum pregnancy test (female of childbearing potential)
Have an implanted defibrillator or pacemaker
Current alcohol or substance use
A history of malignancy within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive carcinoma.
Received solid organ or bone marrow transplant
Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage).
Significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses), or multiple bone fractures
Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1
Subjects on hemodialysis, other forms of renal replacement therapy, or on treatment for underlying kidney diseases (including prednisolone, and dexamethasone)
Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements
Investigational agents (unless approved by Gilead Sciences). Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial
Clareo Health | Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
